Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- A lesson in editing genes: St. Paul firm's hornless cow had a plasmid it wasn't supposed toon September 6, 2019 at 3:21 pm
A Minnesota gene-editing company that designed a hornless dairy bull in a lab five years ago found out the hard way that something went wrong in its editing process. Scientists at the Food and Drug ...
- ETFs Poised to Benefit from Gene Editing Revolutionon September 6, 2019 at 2:51 pm
A decade ago it would have been hard to believe that someone has created a gene-edited human baby or a human-animal hybrid embryo or has cured diabetes and obesity by making some changes in the DNA.
- Chinese biologists trial new gene-editing toolon September 6, 2019 at 5:50 am
(MENAFN - Asia Times) Chinese biologists say they have created an ethical technology to edit RNA – a molecule essential in coding, decoding and expression of genes. They claim it will have "no ...
- Gene Whiz!on September 5, 2019 at 7:15 am
It’s the process of gene editing, and new discoveries in this field have caused it to be one of the most promising scientific developments of the 21st century. Companies making significant ...
- The Swiss Army knife of gene editing gets new controlon September 5, 2019 at 4:49 am
When researchers want to edit, activate, or silence a gene in any living organism, from bacteria to humans, they often turn to CRISPR/Cas9, a complex of RNA and protein that can act like a genetic ...
- Gene editing could double life of guide dogs, say studentson September 5, 2019 at 3:42 am
A start-up is hoping to create genetically modified guide dogs that can live longer. The group of Masters students from Oxford University claim to have found a way to use a gene-editing tool called ...
- FDA Finds Unexpected Antibiotic Resistance Genes in ‘Gene-Edited’ Dehorned Cattleon September 5, 2019 at 1:49 am
Gene-editing is seen by many as the ultimate in precision breeding. Polled cattle, whose horns have been genetically removed, have been presented as exemplars of this–a socially beneficial use of ...
- The first gene-edited lizard walks among uson September 4, 2019 at 2:44 pm
"For quite some time we've been wrestling with how to modify reptile genomes and manipulate genes in reptiles, but we've been stuck in the mode of how gene editing is being done in the major model ...
- A CRISPR Doyen Discusses Gene-Editing Challengeson September 4, 2019 at 5:32 am
Jennifer Doudna, winner of the 2018 Kavli Prize in Nanoscience, talks to Scientific American about what it’s like to work in perhaps the hottest research area in all of biology. She also discusses the ...
- Editas Medicine: A Good Proxy For The Gene Editing Spaceon September 3, 2019 at 10:04 pm
Today, we take an in-depth look at Editas Medicine. While years away from potential commercialization, it is an intriguing name in the emerging gene editing space. A full investment analysis of ...
via Bing News